Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Subscribe To Our Newsletter & Stay Updated
